PURPOSE/ OBJECTIVES: Stereotactic radiosurgery (SRS) is used as a treatment option for breast cancer brain metastases. It is unclear what factors predict neurologic death for these patients. MATERIALS/ METHODS: A total of 128 patients with breast cancer brain metastases were treated with upfront SRS alone in this study. Survival was estimated using the Kaplan-Meier method. Clinicopathologic factors evaluated included age, ER/PR status, Her2 status, numbers of brain metastases treated, minimum SRS dose, disease-specific GPA, extracranial disease status and systemic disease burden. RESULTS: ER or PR positivity was associated with a trend towards decreased neurologic death (subdistribution hazard ratio (sHR) = 0.54, p=0.06). Factors associated with non-neurologic death include extracranial disease status (sHR = 2.02, p=0.02) and dose (sHR = 1.11, p=0.02); Her2-positivity was associated with reduced hazard of non-neurologic death (sHR 0.52, p=0.05). CONCLUSIONS: ER/PR positivity was associated with a trend towards less neurologic death. HER2 positivity was associated with a trend towards less non-neurologic death.
PURPOSE/ OBJECTIVES: Stereotactic radiosurgery (SRS) is used as a treatment option for breast cancer brain metastases. It is unclear what factors predict neurologic death for these patients. MATERIALS/ METHODS: A total of 128 patients with breast cancer brain metastases were treated with upfront SRS alone in this study. Survival was estimated using the Kaplan-Meier method. Clinicopathologic factors evaluated included age, ER/PR status, Her2 status, numbers of brain metastases treated, minimum SRS dose, disease-specific GPA, extracranial disease status and systemic disease burden. RESULTS: ER or PR positivity was associated with a trend towards decreased neurologic death (subdistribution hazard ratio (sHR) = 0.54, p=0.06). Factors associated with non-neurologic death include extracranial disease status (sHR = 2.02, p=0.02) and dose (sHR = 1.11, p=0.02); Her2-positivity was associated with reduced hazard of non-neurologic death (sHR 0.52, p=0.05). CONCLUSIONS: ER/PR positivity was associated with a trend towards less neurologic death. HER2 positivity was associated with a trend towards less non-neurologic death.
Entities:
Keywords:
brain metastases; breast cancer; breast cancer metastases; neurologic death; prognostic factors
Authors: E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan Journal: Int J Radiat Oncol Biol Phys Date: 2000-05-01 Impact factor: 7.038
Authors: Diandra N Ayala-Peacock; Albert Attia; Steve E Braunstein; Manmeet S Ahluwalia; Jaroslaw Hepel; Caroline Chung; Joseph Contessa; Emory McTyre; Ann M Peiffer; John T Lucas; Scott Isom; Nicholas M Pajewski; Rupesh Kotecha; Mark J Stavas; Brandi R Page; Lawrence Kleinberg; Colette Shen; Robert B Taylor; Nasarachi E Onyeuku; Andrew T Hyde; Daniel Gorovets; Samuel T Chao; Christopher Corso; Jimmy Ruiz; Kounosuke Watabe; Stephen B Tatter; Gelareh Zadeh; Veronica L S Chiang; John B Fiveash; Michael D Chan Journal: J Neurooncol Date: 2017-08-21 Impact factor: 4.130
Authors: Edina C Wang; Andrew J Huang; Karen E Huang; Emory R McTyre; Hui-Wen Lo; Kounosuke Watabe; Linda Metheny-Barlow; Adrian W Laxton; Stephen B Tatter; Roy E Strowd; Michael D Chan; Brandi R Page Journal: J Clin Neurosci Date: 2017-05-13 Impact factor: 1.961
Authors: Emory R McTyre; Adam G Johnson; Jimmy Ruiz; Scott Isom; John T Lucas; William H Hinson; Kounosuke Watabe; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300
Authors: John T Lucas; Hentry G Colmer; Lance White; Nora Fitzgerald; Scott Isom; John D Bourland; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-23 Impact factor: 7.038
Authors: Frank Mu; John T Lucas; Jonathan M Watts; Annette J Johnson; J Daniel Bourland; Adrian W Laxton; Michael D Chan; Stephen B Tatter Journal: J Clin Neurosci Date: 2015-01-02 Impact factor: 1.961
Authors: Andrew J Huang; Karen E Huang; Brandi R Page; Diandra N Ayala-Peacock; John T Lucas; Glenn J Lesser; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: J Neurooncol Date: 2014-07-22 Impact factor: 4.130
Authors: Scott C Lester; Glen B Taksler; J Griff Kuremsky; John T Lucas; Diandra N Ayala-Peacock; David M Randolph; J Daniel Bourland; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Cancer Date: 2013-10-21 Impact factor: 6.921
Authors: Matthew T Neal; Michael D Chan; John T Lucas; Amritraj Loganathan; Christine Dillingham; Edward Pan; John H Stewart; J Daniel Bourland; Edward G Shaw; Stephen B Tatter; Thomas L Ellis Journal: World Neurosurg Date: 2013-02-10 Impact factor: 2.104
Authors: Evan D Bander; Melissa Yuan; Anne S Reiner; Katherine S Panageas; Åse M Ballangrud; Cameron W Brennan; Kathryn Beal; Viviane Tabar; Nelson S Moss Journal: Neurooncol Pract Date: 2021-01-21
Authors: Kevin Armstrong; Jennifer Ward; Mary Dunne; Luke Rock; Jennifer Westrup; Christopher R Mascott; Pierre Thirion; Alina Mihaela Mihai Journal: Front Oncol Date: 2019-05-28 Impact factor: 6.244